Citigroup’s Rocket Pharmaceuticals RCKT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
– Sell
-59,900
Closed -$400K – 5859
2025
Q1
$400K Buy
+59,900
New +$592K ﹤0.01% 3799

Other funds holding RCKT

Citigroup's RCKT Position: Q3 2026 in Review

Citigroup reduced its Rocket Pharmaceuticals (RCKT) stake by 5.3% in Q3 2026, selling an estimated $888K and leaving 4,609,231 shares worth $12.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1490.

Citigroup first reported a position in RCKT in Q1 2015 and has held it in 41 quarters since. The position peaked at $18.4M in Q4 2025. 174 funds tracked by Wall St. Rank hold RCKT as of Q3 2026.

  • Citigroup held 4,609,231 shares of Rocket Pharmaceuticals worth $12.1M as of Q3 2026.
  • Citigroup sold 256,320 Rocket Pharmaceuticals shares in Q3 2026, an estimated $888K.
  • Rocket Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #1490 holding.
  • Citigroup first reported a position in Rocket Pharmaceuticals in Q1 2015 and has held it in 41 quarters since.
  • Citigroup's Rocket Pharmaceuticals position peaked at $18.4M in Q4 2025.
  • 174 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.